Article Versions Notes

Levens AD, den Haan MC, Jukema JW, Heringa M, van den Hout WB, Moes DJAR, Swen JJ. Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes. 2023; 14(3):578. https://doi.org/10.3390/genes14030578

Levens, Amar D., Melina C. den Haan, J. Wouter Jukema, Mette Heringa, Wilbert B. van den Hout, Dirk Jan A. R. Moes, and Jesse J. Swen. 2023. "Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors" Genes 14, no. 3: 578. https://doi.org/10.3390/genes14030578

Levens, A. D., den Haan, M. C., Jukema, J. W., Heringa, M., van den Hout, W. B., Moes, D. J. A. R., & Swen, J. J. (2023). Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Genes, 14(3), 578. https://doi.org/10.3390/genes14030578